|
|||||
教育背景 |
|||||
University of New York Clinical Research Methods Remote Training Program(2021) |
|||||
北京大学理学博士(2020) |
|||||
北京大学中国医院协会临床药师师资研修班(2017) |
|||||
AphA Delivering Medication Therapy Management Service faculty training program(2017) |
|||||
Duke University—Peking University Global Health Diploma program(2015) |
|||||
清华大学工商管理研修班(2014) |
|||||
北京大学理学硕士(2011) |
|||||
北京大学理学学士(2009) |
|||||
|
|
||||
工作经历 |
|||||
2023.07-2023.12 University of Manchester, Academic Visitor |
|||||
2021.08-至今 北京大学第三医院药学部,副教授 |
|||||
2011.08-至今 北京大学第三医院药学部,药师/主管药师/副主任药师 |
|||||
|
|
||||
社会兼职 |
|||||
国际实践指南注册平台秘书 国际血管联盟(IUA)中国分部专家委员会委员 中国医师协会循证医学专业委员会循证临床药学组委员 中国老年保健医学研究会老年脑血管病分会委员 中国老年保健协会药品和器械合理使用与风险评估分会委员 全国研究生教育评估监测专家库专家 国家科技专家库专家 国家公立医院改革与高质量发展示范项目指导专家 高等学校叙事医学实践教育联盟委员 北京知识产权法院技术调查官 北京市科协人才举荐评审专家 北京市科学技术委员会、中关村科技园区管理委员会科技项目评审专家库专家 北京市医药卫生科技创新成果转化专家库专家 北京药师协会药物治疗管理专业委员会常务委员 北京药学会监管科学与药物经济学专业委员会委员 北京药学会抗感染药物治疗专业委员会委员 北京神经科学学会自由基专业委员会委员 北京大学医学部药品上市后安全性评价中心兼职专家 中国药科大学药学硕士专业学位研究生校外导师 北京大学第三医院学术带头人后备人选 《中国药房》杂志第一届及第二届青年编委会副主编 《临床药物治疗杂志》青年编委会副主编 《中国医院用药评价与分析》青年编委 《BMJ Quality & Safety中文版》青年编委 《American Journal of Health-System Pharmacy中文版》青年编委 |
|||||
|
|
||||
代表性论文(近5年) |
|||||
1.Mu L, Xu J, Ye XM, Jiang YX, Yi ZM*. Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data. BMC Pharmacology and Toxicology. 2025; 26:54. 2.Li CX#*, Sun LC#, Wang YQ, Liu TT, Cai JR, Liu H, Ren Z, Yi ZM*. The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis. Hum Genomics. 2024;18(1):135. 3.Li WT, Zhang H, Zhang Y, Wang K, Hui JJ, Yi ZM*. Comparison of the effectiveness, safety and costs of anti-Parkinson drugs: A multiple-center retrospective study. CNS Neurosci Ther. 2024;30(4):e14531. 4.Ma Y#, Song Z#, Li X, Jiang D, Zhao R*, Yi ZM*. Toward genetic testing of rivaroxaban? insights from a systematic review on the role of genetic polymorphism in rivaroxaban therapy. Clin Pharmacokinet. 2024;63(3):279-291. 5.Yi ZM#*, Mao Y#, He C, Zhang Y, Zhou J, Feng XL*. Medication adherence and costs of medical care among patients with Parkinson's disease: an observational study using electronic medical records. BMC Public Health. 2024;24(1):1202. 6.Li X#, Song Z#, Yi ZM#, Qin J, Jiang D, Wang Z, Li H, Zhao R*. Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review. Ther Adv Med Oncol. 2024;16:17588359241250130. 7.Yi ZM#, Li X#, Wang Z, Qin J, Jiang D, Tian P, Yang P, Zhao R*. Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument. Clin Pharmacokinet. 2023;62(9):1201-1217. 8.Zhang ZH, Yue Sun LC, Gu HY, Jiang DC*, Yi ZM*. Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis. Pharmacogenomics. 2023;24(8):475-484. 9.Meng Q, Gu H, Zhang Q, Yi ZM*, Jiang DC*. Carbamazepine cutaneous adverse reactions and HLA gene variation in the Chinese population: a systematic review and meta-analysis. Pharmacogenomics. 2023;24(8):459-474. 10.Wang R, Li X, Gu X, Cai Q, Wang Y, Yi ZM*, Chen LC. The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis. Front Public Health. 2023;11:1159119. 11.Wang K, Liu ZH, Li XY, Li YF, Li JR, Hui JJ, Li JX, Zhou JW*, Yi ZM*. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1134472. 12.Wang Q, Wu ZY, Tang HL, Yi ZM*, Zhai SD*. The efficacy and safety of prophylactic antibiotics for post-acute stroke infection: A systematic review and meta-analysis. Br J Clin Pharmacol. 2023;89(3):946-955. 13.Yi ZM, Li XY, Wang YB, Wang RL, Ma QC, Zhao RS*, Chen LC. Evaluating the direct medical cost, drug utilization and expenditure for managing Parkinson's disease: a costing study at a medical center in China. Ann Transl Med. 2022;10(6):330. 14.Yi ZM, Willis S, Zhang Y, Liu N, Tang QY, Zhai SD*. Impact of a Collaborative Pharmaceutical Care Service for Patients With Parkinson's Disease. Front Pharmacol. 2022;12:793361. 15.Yi ZM#, Song ZW#, Li XY, Hu Y, Cheng YC, Wang GR, Zhao RS*. The implementation of a FIP guidance for COVID-19: insights from a nationwide survey. Ann Transl Med. 2021;9(18):1479. 16.Yi ZM, Hu Y, Wang GR, Zhao RS*. Mapping Evidence of Pharmacy Services for COVID-19 in China. Front Pharmacol. 2020,11:555753. 17.Yi ZM#, Zhong XL#, Wang ML, Zhang Y, Zhai SD*. Efficacy, safety and economics of intravenous levetiracetam for status epilepticus: a systematic review and meta-analysis. Front Pharmacol. 2020,11:751. 18.Yi ZM#, Men P#, Qu S, Xiong T, Li C, Yu X, Zhai SD*. Comparative Cost-Effectiveness of Amisulpride and Olanzapine in the Treatment of Schizophrenia in China. Expert Rev Pharmacoecon Outcomes Res. 2020; 20:313-320. |
|||||
|
|||||
荣誉奖励 |
|||||
2024年,《中国药房》“优秀青年编委” 2024年,中国知网高被引学者TOP 5% 2023年,江苏省执业药师继续教育课件竞评二等奖 2022年,北京药学会优秀药师 2022年,中国管理科学学会“管理科学奖”(5/8) 2021年,中国医院协会医院科技创新奖三等奖(7/15) 2021年,University of New York Completion with Honors/Top Performing Trainee 2021年,北京大学教学成果奖二等奖(4/16) 2021年,北京大学医学部教学成果奖二等奖(4/16) 2020年,中国药学会科学技术奖三等奖(10/20) 2018年,中国药学会科学技术奖三等奖(6/14) 2018年,北京大学学术创新奖 2017年,北京大学医学部教学成果奖三等奖(3/8) 2017年,北京大学医学部优秀教学团队 2016年,中华医学会临床药学分会“优秀临床药师” 2015年,北京大学医学部优秀团干部 2014年,北京大学第三医院优秀教师 2011-2024年,获得中国药学大会、全国医院药学学术年会、中华医学会医学教育分会、中华医学会临床药学分会、 全国治疗药物检测学术年会、北京药学会学术年会、紫禁城国际药师大会等优秀论文 |